Your Passport to the Newsiverse
Shares of Sun Pharmaceuticals, India’s largest drug manufacturer, gained more than 50% over the last one year. In its latest results, the company also posted a 34% on year jump in Q4 profit. While the stock did decline slightly this week, pharma analysts are positive on the stock as the company has shown growth across key therapies. The biggest reason for optimism is Sun Pharma’s global specialty business, which exceeded USD1 billion in sales in
Image credit: Compiled by Manali Ghosh via AI Synopsis Advent controlled-BSV has charted an exceptional turnaround over the last five years, seeing a 3x jump in its valuation. Its specialised products in women’s health and a robust research pipeline makes it a cynosure of all eyes. As the bidding race to buy BSV intensifies, ET […]
YK Hamied, non-executive chairman, Cipla Synopsis Cipla may be privately owned, but effectively it has been a ‘national asset’ — with each brick representing Indian ingenuity, enterprise, and strength of character. While shareholders will most likely have no reason to complain, the end losers of Cipla’s founding family’s potential exit will be millions of underprivileged […]
Dilip Shanghvi , founder, chairman and managing director, Sun Pharmaceutical Industries Limited. Synopsis Selling weight-loss drugs is an opportunity no pharma company wants to miss. Now a leading drug maker from India joins this bandwagon. Trust Sun Pharma boss Dilip Shanghvi to be at the cutting-edge of research. After building a band of specialty drugs […]